Added to YB: 2026-10-09
Pitch date: 2026-10-04
PMVP [bullish]
PMV Pharmaceuticals, Inc.
-28.33%
current return
Author Info
No bio for this author
Company Info
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States.
Market Cap
$121.6M
Pitch Price
$1.80
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.54
P/E
-1.14
EV/Sales
N/A
Sector
Biotechnology
Category
growth
M&A Hunter Portfolio Update: Tier 3 Core Convictions (Under $10) - PMV Pharmaceuticals, Inc.
PMVP (hold): PMV Pharmaceuticals is a p53-reactivation story targeting one of oncology’s most important and historically difficult target classes. Strategic interest depends on producing deep, durable and tolerable responses in a defined p53-mutant population that a larger buyer can underwrite; until the program demonstrates a partnerable profile beyond a narrow early dataset, PMV lacks a franchise and remains primarily a chemistry-and-clinical-signal bet.
Read full article (1 min)